Guangdong Marubi Biotechnology Co (603983) — Net Asset Quality Index
Guangdong Marubi Biotechnology Co (603983) has a Net Asset Quality Index of 74.5% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥4.69 Billion minus total liabilities of CN¥1.20 Billion yields net assets of CN¥3.49 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Guangdong Marubi Biotechnology Co (603983) financial obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Guangdong Marubi Biotechnology Co Net Asset Quality Index Over Time (2011–2025)
This chart shows how Guangdong Marubi Biotechnology Co's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the index stands at 74.5%, representing net assets of CN¥3.49 Billion against total assets of CN¥4.69 Billion CNY. For live market cap and overall valuation, see Guangdong Marubi Biotechnology Co market capitalisation.
Annual Net Asset Quality Index for Guangdong Marubi Biotechnology Co (2011–2025)
The table below presents the year-by-year Net Asset Quality Index for Guangdong Marubi Biotechnology Co from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check strategic asset allocation of Guangdong Marubi Biotechnology Co to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 73.6% | CN¥3.39 Billion | CN¥4.61 Billion | CN¥1.22 Billion | ▲ +5.5 pp |
| 2024 | 68.1% | CN¥3.45 Billion | CN¥5.06 Billion | CN¥1.62 Billion | ▼ -8.7 pp |
| 2023 | 76.8% | CN¥3.42 Billion | CN¥4.45 Billion | CN¥1.04 Billion | ▼ -2.7 pp |
| 2022 | 79.5% | CN¥3.25 Billion | CN¥4.09 Billion | CN¥838.64 Million | ▼ -4.5 pp |
| 2021 | 84.0% | CN¥3.16 Billion | CN¥3.76 Billion | CN¥603.19 Million | ▲ +4.9 pp |
| 2020 | 79.1% | CN¥3.00 Billion | CN¥3.80 Billion | CN¥794.44 Million | ▲ +1.4 pp |
| 2019 | 77.7% | CN¥2.67 Billion | CN¥3.44 Billion | CN¥766.40 Million | ▲ +12.4 pp |
| 2018 | 65.3% | CN¥1.38 Billion | CN¥2.12 Billion | CN¥735.02 Million | ▲ +5.4 pp |
| 2017 | 59.9% | CN¥959.96 Million | CN¥1.60 Billion | CN¥643.00 Million | ▲ +3.8 pp |
| 2016 | 56.1% | CN¥828.09 Million | CN¥1.48 Billion | CN¥647.79 Million | ▲ +3.7 pp |
| 2015 | 52.4% | CN¥715.92 Million | CN¥1.37 Billion | CN¥649.88 Million | ▲ +2.1 pp |
| 2014 | 50.3% | CN¥604.48 Million | CN¥1.20 Billion | CN¥597.49 Million | ▲ +2.0 pp |
| 2013 | 48.2% | CN¥453.11 Million | CN¥939.25 Million | CN¥486.14 Million | ▲ +14.9 pp |
| 2012 | 33.3% | CN¥234.87 Million | CN¥704.69 Million | CN¥469.82 Million | ▲ +8.5 pp |
| 2011 | 24.8% | CN¥148.02 Million | CN¥596.96 Million | CN¥448.94 Million | — |